Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Changes to anti-JCV antibody levels in a Swedish national MS cohort.
Activation of axonal Kv7 channels in human peripheral nerve by flupirtine but not placebo - therapeutic potential for peripheral neuropathies: results of a randomised controlled trial.
Treatment with 4-aminopyridine improves upper limb tremor of a patient with multiple sclerosis: a video case report.
The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α
Design, engineering, and production of human recombinant t cell receptor ligands derived from human leukocyte antigen DR2.
Emerging roles of endothelial cells in multiple sclerosis pathophysiology and therapy.
The Stigma Scale for Chronic Illnesses 8-Item Version (SSCI-8): Development, Validation and Use Across Neurological Conditions.
The multiple sclerosis rating scale, revised (MSRS-R): Development, refinement, and psychometric validation using an online community.
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
Molecular properties of epithelial, amiloride-blockable Na+ channels.
Disease-modifying treatments for progressive multiple sclerosis.
A complex role of herpes viruses in the disease process of multiple sclerosis.
Epigenetic changes in patients with multiple sclerosis.
Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica.
Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.
Phase II Cladribine Add-on to Interferon-beta (IFN-b) Therapy in MS Subjecs With Active Disease (ONWARD)
Cardiotoxicity of mitoxantrone treatment in a german cohort of 639 multiple sclerosis patients.
Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies.
Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis.
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
Effect of lipoic acid consumption on oxidative stress among multiple sclerosis patients: A randomized controlled clinical trial.
Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome.
Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
Saccadic intrusions: review and update.

Pages